Article
Oncology
Simon Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot
Summary: This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX failure. The results show that Gem-Nab is associated with better disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared with Gem alone, but with higher toxicity.
BRITISH JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Avital Klein-Brill, Shlomit Amar-Farkash, Gabriella Lawrence, Eric A. Collisson, Dvir Aran
Summary: This study compared the two common first-line treatments for metastatic adenocarcinoma of the pancreas, FOLFIRINOX and gemcitabine plus nab-paclitaxel, and found that FOLFIRINOX was associated with improved overall survival and fewer posttreatment complications.
Article
Oncology
Patrick M. Grierson, Benjamin Tan, Katrina S. Pedersen, Haeseong Park, Rama Suresh, Manik A. Amin, Nikolaos A. Trikalinos, Deborah Knoerzer, Brent Kreider, Anupama Reddy, Jingxia Liu, Channing J. Der, Andrea Wang-Gillam, Kian-Huat Lim
Summary: This study evaluated the efficacy and safety of ulixertinib combined with gemcitabine and nab-paclitaxel (GnP) for untreated metastatic pancreatic adenocarcinoma. The results showed that ulixertinib plus GnP had similar toxicity and efficacy as GnP, but was complicated by a high rate of all-grade treatment-related adverse events (TRAEs).
Article
Oncology
M. Tempero, D-Y Oh, J. Tabernero, M. Reni, E. Van Cutsem, A. Hendifar, D-T Waldschmidt, N. Starling, J-B Bachet, H-M Chang, J. Maurel, R. Garcia-Carbonero, S. Lonardi, L. M. Coussens, L. Fong, L. C. Tsao, G. Cole, D. James, T. Macarulla
Summary: This study evaluated the safety and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PDAC. Results showed that although there were differences in overall response rates, ibrutinib plus nab-paclitaxel/gemcitabine did not improve overall survival or progression-free survival for patients with PDAC. Additionally, patients in the ibrutinib arm received lower cumulative drug doses.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Chen Chang, Xiaofen Li, Ke Cheng, Zhaolun Cai, Junjie Xiong, Wanrui Lv, Ruizhen Li, Pei Zhang, Dan Cao
Summary: The study evaluated the toxicity and feasibility of gemcitabine/nab-paclitaxel/S-1 (GAS) chemotherapy on a 21-day cycle in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results showed that GAS chemotherapy had acceptable toxicity and significant clinical control in these patients.
Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Sheron Perera, Gun Ho Jang, Yifan Wang, Deirdre Kelly, Michael Allen, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Mustapha Tehfe, Ravi Ramjeesingh, James Biagi, Bernard Lam, Julie Wilson, Sandra E. Fischer, George Zogopoulos, Faiyaz Notta, Steven Gallinger, Robert C. Grant, Jennifer J. Knox, Grainne M. O'Kane
Summary: In advanced PDAC, hENT1 mRNA expression predicts ORR and OS in patients receiving GnP, while no association was observed in patients receiving mFFX.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Alberto Servetto, Antonio Santaniello, Fabiana Napolitano, Francesca Foschini, Roberta Marciano, Priscilla Cascetta, Anna Rita Amato, Maria Rosaria Augurio, Lucia Maresca, Pietro De Placido, Sabino De Placido, Luigi Formisano, Roberto Bianco
Summary: This study compared the clinical outcomes of first-line FOLFIRINOX and nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. The results showed that there were no significant differences in median progression-free survival and median overall survival between first-line FFN and NabGem. In patients receiving NabGem, second-line FFN may improve survival and progression-free survival.
Article
Medicine, General & Internal
Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem
Summary: In an open-label phase 3 study, it was found that the addition of napabucasin to nab-paclitaxel with gemcitabine did not improve efficacy in patients with previously untreated metastatic pancreatic adenocarcinoma (mPDAC). However, the safety profile of napabucasin was consistent with previous reports. This study reinforced the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutic approaches in mPDAC.
Article
Oncology
Kimberly Perez, Anna M. Chiarella, James M. Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A. Meyerhardt, Douglas Rubinson, Matthew B. Yurgelun, Wolfram Goessling, Bruce J. Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R. Pitarresi, Andrew J. Aguirre, Michael Needle, Anil K. Rustgi, Brian M. Wolpin
Summary: This article evaluates the safety profile and clinical efficacy of ficlatuzumab in combination with gemcitabine and albumin-bound paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The study showed that this combination therapy can lead to durable treatment responses and increased rates of hypoalbuminemia and edema.
Article
Oncology
Kimberly Perez, Anna M. Chiarella, James M. Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A. Meyerhardt, Douglas Rubinson, Matthew B. Yurgelun, Wolfram Goessling, Bruce J. Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R. Pitarresi, Andrew J. Aguirre, Michael Needle, Anil K. Rustgi, Brian M. Wolpin
Summary: In this study, the combination of ficlatuzumab, gemcitabine, and albumin-bound paclitaxel showed durable treatment responses but also increased rates of hypoalbuminemia and edema.
Article
Medicine, General & Internal
Zev A. Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R. Chandana, Christelle De La Fouchardiere, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten O. Goetze, Eric Van Cutsem, A. Scott Paulson, Tanios Bekaii-Saab, Shubham Pant, Richard A. Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen M. O'Reilly
Summary: The study findings support the use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC.
Article
Oncology
Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella
Summary: This retrospective study investigated the use of pancreatic enzyme replacement therapy (PERT) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing chemotherapy, and found that PERT was associated with significantly prolonged survival and alleviation of maldigestion-related symptoms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti
Summary: The study found that FFX and GN have equivalent efficacy in first-line treatment of metastatic pancreatic cancer, but differ in safety profiles. Anemia was more frequent in the GN group, while higher occurrences of vomiting and diarrhea were reported in the FFX group.
Article
Oncology
E. Assenat, C. de la Fouchardiere, F. Portales, M. Ychou, A. Debourdeau, F. Desseigne, S. Iltache, C. Fiess, C. Mollevi, T. Mazard
Summary: The study evaluated a new first-line sequential treatment using AG and FFX drugs in metastatic pancreatic cancer, showing acceptable toxicity, high response rate, and longer survival. Further randomized trials are justified to validate these findings.
Article
Oncology
Rishi Jain, Jia-Llon Yee, Talha Shaikh, Cherry Au, Elizabeth Handorf, Joshua E. Meyer, Efrat Dotan
JOURNAL OF GERIATRIC ONCOLOGY
(2020)
Article
Oncology
Rishi Jain, Namrata Vijayvergia, Karthik Devarajan, Bianca Lewis, Crystal S. Denlinger, Steven J. Cohen, Efrat Dotan
JOURNAL OF GERIATRIC ONCOLOGY
(2020)
Article
Oncology
Namrata Vijayvergia, Arvind Dasari, Mengying Deng, Samuel Litwin, Taymeyah Al-Toubah, R. Katherine Alpaugh, Efrat Dotan, Michael J. Hall, Nicole M. Ross, Melissa M. Runyen, Crystal S. Denlinger, Daniel M. Halperin, Steven J. Cohen, Paul F. Engstrom, Jonathan R. Strosberg
BRITISH JOURNAL OF CANCER
(2020)
Article
Oncology
Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S. Paulson, Mitesh J. Borad, David Gallinson, Adrian G. Murphy, Do-Youn Oh, Efrat Dotan, Daniel Catenacci, Eric Van Cutsem, Tao Ji, Christine F. Lihou, Huiling Zhen, Luis Feliz, Arndt Vogel
Article
Oncology
Arthur Winer, Crystal S. Denlinger, Namrata Vijayvergia, Steven J. Cohen, Igor Astaturov, Efrat Dotan, Jean-Nicolas Gallant, Edward W. Wang, Miriam Kunkel, Bora Lim, Harold A. Harvey, Jeffrey Sivik, Kenneth Korzekwa, Karen Ruth, Kevin White, Harry S. Cooper, Eric A. Ross, Lanlan Zhou, Wafik S. El-Deiry
Summary: Quinacrine and 5-fluorouracil (5-FU) show preclinical activity against colorectal cancer, with the combination of quinacrine and the 5-FU analog capecitabine demonstrating safety and efficacy in some patients with treatment-refractory metastatic CRC. The maximum tolerated dose was identified, with 1 partial response and 5 stable disease observed. This regimen could be considered for patients with treatment-refractory mCRC, as it showed activity in heavily pretreated patients despite the early halt of the expansion study.
CLINICAL COLORECTAL CANCER
(2021)
Article
Oncology
Allison Magnuson, Mina S. Sedrak, Cary P. Gross, William P. Tew, Heidi D. Klepin, Tanya M. Wildes, Hyman B. Muss, Efrat Dotan, Rachel A. Freedman, Tracey O'Connor, William Dale, Harvey J. Cohen, Vani Katheria, Anait Arsenyan, Abrahm Levi, Heeyoung Kim, Supriya Mohile, Arti Hurria, Can-Lan Sun
Summary: The study identified 8 independent predictors and developed a scoring model to predict chemotherapy toxicity in older adults with early-stage breast cancer. Patients were classified into low, intermediate, and high-risk groups, aiding in the early prediction of toxic reactions.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Geriatrics & Gerontology
Erika Correa, Timothy Lindsay, Efrat Dotan
Summary: As the population ages, the number of older patients with mCRC is increasing, requiring personalized treatment approaches and highlighting the importance of managing older adults. A comprehensive geriatric assessment can assist in selecting appropriate treatment options, with particular importance for frail older patients.
Article
Oncology
Ravi B. Parikh, Samuel U. Takvorian, Daniel Vader, E. Paul Wileyto, Amy S. Clark, Daniel J. Lee, Gaurav Goyal, Gabrielle B. Rocque, Efrat Dotan, Daniel M. Geynisman, Pooja Phull, Philippe E. Spiess, Roger Y. Kim, Amy J. Davidoff, Cary P. Gross, Natalia Neparidze, Rebecca A. Miksad, Gregory S. Calip, Caleb M. Hearn, Will Ferrell, Lawrence N. Shulman, Ronac Mamtani, Rebecca A. Hubbard
Summary: Despite the COVID-19 pandemic causing delays in patients seeking treatment for life-threatening conditions, it did not affect the time to treatment initiation or treatment selection for newly diagnosed patients with metastatic solid cancers.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Mina S. Sedrak, Can-Lan Sun, Jingran Ji, Harvey J. Cohen, Cary P. Gross, William P. Tew, Heidi D. Klepin, Tanya M. Wildes, Efrat Dotan, Rachel A. Freedman, Tracey O'Connor, Selina Chow, Mary Ann Fenton, Beverly Moy, Andrew E. Chapman, William Dale, Vani Katheria, Nicole M. Kuderer, Gary H. Lyman, Allison Magnuson, Hyman B. Muss
Summary: Older women with high-risk early breast cancer often suffer from toxic side effects during adjuvant chemotherapy, leading to dose reductions and delays. Identifying women at risk of receiving suboptimal dose intensity may improve treatment discussions and guide early supportive care interventions.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Dina Ioffe, Efrat Dotan
Summary: The need for more evidence-based studies specifically targeting the elderly population is crucial in the rapidly growing group of older patients. It is important to interpret existing data on overall survival with caution, as many of these studies did not initially include age stratification. While waiting for data from ongoing elderly-specific trials, it is recommended to use geriatric screening tools for treatment adjustments in older patients with colorectal cancer, and a full geriatric assessment for those with significant geriatric concerns.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Shannon Stockton, Paul Catalano, Steven J. Cohen, Barbara A. Burtness, Edith P. Mitchell, Efrat Dotan, Sam J. Lubner, Pankaj Kumar, Mary F. Mulcahy, George A. Fisher, Theodore L. Crandall, Al Benson
Summary: This randomized phase II trial compared the efficacy of paclitaxel (arm A) and paclitaxel plus cixutumumab (arm B) as second-line therapy for patients with metastatic esophageal or gastroesophageal junction cancers. The results showed that the addition of cixutumumab to paclitaxel did not significantly improve clinical outcomes, including progression-free survival and overall survival, compared to standard of care. Therefore, cixutumumab did not show enhanced efficacy when combined with paclitaxel in the treatment of metastatic esophageal/GEJ cancer.
Article
Oncology
Aaron J. Scott, Atrayee Basu Mallick, Efrat Dotan, Steven J. Cohen, Philip J. Gold, Howard S. Hochster, Somasundaram Subramaniam, Afsaneh Barzi, George S. Watts, Patrick J. Blatchford, Wells A. Messersmith
Summary: This study demonstrated the clinical activity of cabozantinib in patients with refractory metastatic colorectal cancer, suggesting its potential as a therapeutic option.
CANCER RESEARCH COMMUNICATIONS
(2022)
Article
Oncology
Pritish Iyer, Mengying Deng, Elizabeth A. Handorf, Shazia Nakhoda, Efrat Dotan
Summary: Despite national guideline recommendations, adherence to universal biomarker testing in routine practice for patients with metastatic colorectal cancer is low. However, there has been an increase in testing rates for NRAS, BRAF, and MMR/MSI between 2013 and 2018.
JNCI CANCER SPECTRUM
(2022)
Article
Oncology
Arthur Winer, Elizabeth Handorf, Efrat Dotan
Summary: Retrospective analysis showed that in older mPDAC patients, using the traditional dosing schedule of GA resulted in better overall survival and time on treatment compared to the modified schedule. Prospective studies are needed to ensure optimal treatment strategies for patients.
JNCI CANCER SPECTRUM
(2021)